HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for an inhaled liposomal formulation of ciprofloxacin for the management of bronchiectasis (BE). Aradigm previously received orphan drug designation for the same formulation of ciprofloxacin for the management of cystic fibrosis in April 2006.
